Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 10, Issue 6, 2008, Pages 495-498

  Di Bartolo, Paolo ^a,e   Pellicano, Francesca ^a   Scaramuzza, Antonio ^a   Sardu, Cipriana ^a   Casetti, Tino ^b   Bosi, Emanuele ^c   Miselli, Valerio ^d   Brandolini, Sara ^a   Fabbri, Tiziano ^a   Meandri, Piero ^a   Cannatà, Francesco ^a  

^a Diabetes Unit   (Italy)

^b Ravenna Local Health Unit   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d Scandiano Hospital   (Italy)

^e Department of Digestive and Metabolic Diseases   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN LISPRO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEAL; PATIENT MONITORING; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; EATING; HUMANS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 57349185245     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0013     Document Type: Article

References (12)

1. Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M: Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med 1996;13:625-629.
2. Home PD, Lindholm A, Riis A; European Insulin Aspart Study Group: Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000;17:762-770.
3. Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB: Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 1995;18:1452-1459.
4. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R: Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-270.
5. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-443.
6. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G: Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003;26:2027-2031.
7. Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR: A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-2057.
8. von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J: Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2002;110:416-419.
9. Hedman CA, Lindstrom T, Arnqvist HJ: Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 2001;24:1120-1121.
10. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-1708.
11. Schedina N, Pickup JC: Performance assessment of the Medtronic-MiniMed Continuous Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 diabetic subjects. Diabet Med 2003;20:1012-1015.
12. Selam JL: How to measure glycemic instability? Diabetes Metab 2000;26:148-151.